JP4328750B2 - 新規な化合物、肥満改善剤、脂質代謝改善剤、血糖降下剤及び育毛改善剤 - Google Patents
新規な化合物、肥満改善剤、脂質代謝改善剤、血糖降下剤及び育毛改善剤 Download PDFInfo
- Publication number
- JP4328750B2 JP4328750B2 JP2005265430A JP2005265430A JP4328750B2 JP 4328750 B2 JP4328750 B2 JP 4328750B2 JP 2005265430 A JP2005265430 A JP 2005265430A JP 2005265430 A JP2005265430 A JP 2005265430A JP 4328750 B2 JP4328750 B2 JP 4328750B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- improving agent
- agent
- improving
- obesity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000001875 compounds Chemical class 0.000 title claims description 89
- 239000003795 chemical substances by application Substances 0.000 title claims description 41
- 208000008589 Obesity Diseases 0.000 title claims description 33
- 230000037356 lipid metabolism Effects 0.000 title claims description 21
- 235000020824 obesity Nutrition 0.000 title claims description 19
- 239000003472 antidiabetic agent Substances 0.000 title claims description 18
- 229940126904 hypoglycaemic agent Drugs 0.000 title claims description 18
- 230000003779 hair growth Effects 0.000 title description 31
- 239000004480 active ingredient Substances 0.000 claims description 23
- 210000004209 hair Anatomy 0.000 claims description 22
- 230000009471 action Effects 0.000 description 28
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 27
- 241001122767 Theaceae Species 0.000 description 19
- 230000000694 effects Effects 0.000 description 19
- 239000000284 extract Substances 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 17
- 241000124033 Salix Species 0.000 description 15
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 239000004129 EU approved improving agent Substances 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 230000002218 hypoglycaemic effect Effects 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 230000037396 body weight Effects 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 239000008187 granular material Substances 0.000 description 8
- 150000002632 lipids Chemical class 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 8
- 239000000741 silica gel Substances 0.000 description 8
- 229910002027 silica gel Inorganic materials 0.000 description 8
- 239000002775 capsule Substances 0.000 description 7
- 201000004384 Alopecia Diseases 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 230000000144 pharmacologic effect Effects 0.000 description 6
- 206010003210 Arteriosclerosis Diseases 0.000 description 5
- 208000011775 arteriosclerosis disease Diseases 0.000 description 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 5
- 238000010828 elution Methods 0.000 description 5
- 208000024963 hair loss Diseases 0.000 description 5
- 230000003676 hair loss Effects 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- 239000012488 sample solution Substances 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000005084 2D-nuclear magnetic resonance Methods 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 description 3
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 230000035622 drinking Effects 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 239000000469 ethanolic extract Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 235000009200 high fat diet Nutrition 0.000 description 3
- 230000003752 improving hair Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- -1 lupin acid Chemical class 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000219745 Lupinus Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000002031 ethanolic fraction Substances 0.000 description 2
- 239000004503 fine granule Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000003345 hyperglycaemic effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000001596 intra-abdominal fat Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- 206010061666 Autonomic neuropathy Diseases 0.000 description 1
- 201000004569 Blindness Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 102100028717 Cytosolic 5'-nucleotidase 3A Human genes 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010021024 Hypolipidaemia Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- ZPXSCAKFGYXMGA-UHFFFAOYSA-N Mazindol Chemical compound N12CCN=C2C2=CC=CC=C2C1(O)C1=CC=C(Cl)C=C1 ZPXSCAKFGYXMGA-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical class OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010033647 Pancreatitis acute Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 241000220222 Rosaceae Species 0.000 description 1
- 241000040929 Sibiraea angustata Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 208000024248 Vascular System injury Diseases 0.000 description 1
- 208000012339 Vascular injury Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 201000003229 acute pancreatitis Diseases 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- 239000003263 anabolic agent Substances 0.000 description 1
- 229940070021 anabolic steroids Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000000918 epididymis Anatomy 0.000 description 1
- 201000010063 epididymitis Diseases 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 229960004580 glibenclamide Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 1
- 235000021552 granulated sugar Nutrition 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 208000020346 hyperlipoproteinemia Diseases 0.000 description 1
- 208000026621 hypolipoproteinemia Diseases 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 229960000299 mazindol Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 229960003632 minoxidil Drugs 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 235000002378 plant sterols Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000002966 stenotic effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H23/00—Compounds containing boron, silicon, or a metal, e.g. chelates, vitamin B12
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Non-Alcoholic Beverages (AREA)
- Saccharide Compounds (AREA)
Description
請求項4に記載の血糖降下剤は、請求項1に記載の化合物を有効成分とすることを要旨とする。
本実施形態の化合物(以下、化合物(I)と記載する)は、下式(1)で表されるものである。
この化合物(I)は、例えば、柳茶を水、低級アルコール又は含水低級アルコールで抽出することにより抽出物を得た後、該抽出物をさらに精製することにより得られる。低級アルコールとしては、メタノール、エタノール、ブタノール、プロパノール、イソプロパノール等が使用可能である。含水低級アルコールには、50%以上の低級アルコールが含まれていることが好ましく、80%以上の低級アルコールが含まれていることがより好ましい。
本実施形態の肥満改善剤は、化合物(I)を有効成分として含有し、体重減少作用(体重の増加抑制作用)や体脂肪低下作用(体脂肪の増加抑制作用)等の肥満改善作用を発揮する。本実施形態の脂質代謝改善剤は、化合物(I)を有効成分として含有し、血清コレステロール濃度や血清トリグリセリド濃度の低下作用等の脂質代謝改善作用を発揮する。本実施形態の血糖降下剤は、化合物(I)を有効成分として含有し、血糖降下作用を発揮する。本実施形態の育毛改善作用は、化合物(I)を有効成分として含有し、育毛改善作用を発揮する。
・ 本実施形態の化合物(I)は、上式(1)で表される1−O−グルコシルゲラニオール−10,5−オリドである。この化合物(I)は、天然物由来、より具体的には生薬由来の新規な化合物であるうえ、肥満改善作用、脂質代謝改善作用、血糖降下作用、育毛改善作用等の様々な薬理作用を有している。このため、この化合物(I)は、肥満改善剤、脂質代謝改善剤、血糖降下剤、育毛改善剤等の有効成分として利用することができるため、極めて有用である。
窄葉鮮卑の乾燥枝25.5kgを粉砕後、水で抽出することにより、柳茶の水抽出液を得た。この柳茶の水抽出液を乾燥させることにより、柳茶の水抽出物3.0kgを得た。続いて、この柳茶の水抽出物を3Lのエタノールで3回加熱環流抽出することにより、柳茶のエタノール抽出物1.39kgを得た。
6週齢のddY系雄性SPFマウス(日本エスエルシー社、体重約30g)を1週間予備飼育した後、対照群及び投与群の二群(各群5匹ずつ)に分けた。両群のマウスをそれぞれ高脂肪食(ラード40%、コーンスターチ10%、グラニュー糖9%、ミネラルミックス4%、ビタミンミックス1%、カゼイン29%、セルロース5%、ラクトース2%)にて6週間飼育した。投与群のマウスには、高脂肪食での飼育期間中、化合物(I)を精製水に溶解させた検体溶解液を、1日1回、250mg/kgの投与量で6週間連続飲水投与するとともに、1週間に1回の割合で体重測定を行った。対照群のマウスには、前記検体溶解液の代わりに精製水を6週間飲水投与した。
図9に示すように、高脂肪食を摂取した対照群のマウスでは、体重の急激な増加が認められた。通常の食餌(高炭水化物食)で飼育したマウスについての予備試験の結果を参照すると、これら対照群のマウスでは、明らかに肥満が誘発されていることが確認された。これに対し、化合物(I)を同時に投与した投与群のマウスでは、体重が低い値で推移しており、対照群と比べると統計学的な有意差が認められた。よって、化合物(I)は体重の増加抑制作用を有することが示された。ちなみに、対照群のマウスと投与群のマウスとを比較した場合、飲水投与期間中の摂餌量及び摂水量はほぼ同様であった。
6週齢のC3H系雄性マウス(日本エスエルシー社、体重約30g)を1週間予備飼育した後、対照群及び投与群の二群(各群4匹ずつ)に分けた。両群のマウスの背部の毛を電機シェーバーにてそれぞれ除毛し、育毛効果を検討した。投与群の各マウスには、化合物(I)を45%含水エタノールに溶解させた検体溶解液を、1日1回、0.1mL(化合物(I)の重量に換算すると10mg)の塗布量で、除毛されたマウスの背部の皮膚に2cm×2cmの正方形状に広げるように28日間経皮投与し、1日に1回の割合で発毛状態の観察を行った。対照群のマウスには、前記検体溶解液の代わりに45%含水エタノールを28日間経皮投与した。
発毛スコアの測定は、検体溶解液又は45%含水エタノールを塗布したマウスの背部を肉眼で観察し、除毛直後の状態に対して、変化がない場合は0点、背部中央部が青色に変化した場合は1点、背部中央部が青黒から灰色に変化した場合は2点、背部中央部に発毛が観察された場合は3点、背部中央部の約50%の面積が背毛で覆われ、背部中央部が除毛前の色に復帰した場合は4点のスコアをつけた。そして、各群のマウスのスコアの平均値及び標準誤差を求めた。また、対照群と投与群との間の発毛スコアにバラツキがほとんど見られなかったため、両群間の有意差検定としてMann−WhitneyのU−検定を行った。これらの結果の一部を図10のグラフに示す。
(処方例1)細粒剤
化合物(I)4.10重量部、乳糖0.14重量部、トウモロコシデンプン1.30重量部、無水ケイ酸0.37重量部及びステアリン酸マグネシウム0.09重量部を十分に混合した。この混合物を圧縮形成剤により板状物とした後、オシレーターで粉砕して顆粒状とした。最後に、顆粒を識別することにより、1g中に化合物(I)683mgを含む細粒剤を得た。
化合物(I)3.00重量部、乳糖1.00重量部、トウモロコシデンプン0.50重量部、合成ケイ酸アルミニウム0.20重量部、カルボキシメチルセルロースカルシウム0.25重量部及びステアリン酸マグネシウム0.05重量部を十分に混合した。この混合物を1錠当り300mgが含まれるように打錠して、1錠中に化合物(I)180mgを含む錠剤を得た。
化合物(I)3.34重量部、合成ケイ酸アルミニウム0.18重量部及びステアリン酸マグネシウム0.18重量部を十分に混合した。この混合物370mgをカプセルに充填して、1カプセル中に化合物(I)334mgを含むカプセル剤を得た。
・ 育毛改善剤をシャンプーやリンス等の医薬部外品として利用してもよい。
・ 化合物(I)を、パン、ケーキ、スナック菓子等の嗜好品、牛乳やヨーグルト等の乳製品、清涼飲料等の飲料品に含有させてもよい。
・ 柳茶の抽出物を有効成分とする育毛改善剤を提供することが可能である。柳茶の抽出物としては、上記実施形態の水、低級アルコール又は含水低級アルコール抽出物、あるいは該抽出物を活性炭やシリカゲル等で精製したものが挙げられる。このような柳茶の抽出物には、化合物(I)が含まれているため、育毛改善作用を発揮することができる。ちなみに、柳茶の抽出物を有効成分とする育毛改善剤は、医薬品、医薬部外品又は健康食品の原料として利用可能である。
・ 請求項1に記載の化合物を含有する健康食品。請求項1に記載の化合物を有効成分とする医薬品。請求項1に記載の化合物を含有する医薬部外品。請求項1に記載の化合物を含有する飲食品。
Claims (5)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005265430A JP4328750B2 (ja) | 2005-09-13 | 2005-09-13 | 新規な化合物、肥満改善剤、脂質代謝改善剤、血糖降下剤及び育毛改善剤 |
US11/437,769 US7538137B2 (en) | 2005-09-13 | 2006-05-22 | 1-O-β-D-glucopyranosylgeraniol-10,5-olide and use thereof |
CN2006100924043A CN101077881B (zh) | 2005-09-13 | 2006-05-26 | 1-O-β-D-吡喃葡萄糖基香叶醇-10,5-内酯及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005265430A JP4328750B2 (ja) | 2005-09-13 | 2005-09-13 | 新規な化合物、肥満改善剤、脂質代謝改善剤、血糖降下剤及び育毛改善剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2007077051A JP2007077051A (ja) | 2007-03-29 |
JP4328750B2 true JP4328750B2 (ja) | 2009-09-09 |
Family
ID=37855443
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2005265430A Active JP4328750B2 (ja) | 2005-09-13 | 2005-09-13 | 新規な化合物、肥満改善剤、脂質代謝改善剤、血糖降下剤及び育毛改善剤 |
Country Status (3)
Country | Link |
---|---|
US (1) | US7538137B2 (ja) |
JP (1) | JP4328750B2 (ja) |
CN (1) | CN101077881B (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101732441B (zh) * | 2010-01-22 | 2012-03-07 | 北京师范大学 | 一种预防肥胖症和降低高血脂的柳茶有效部位提取物及其制备方法和用途 |
CN102657717A (zh) * | 2011-04-24 | 2012-09-12 | 兰州大学 | 植物柳茶的用途 |
CN102188515B (zh) * | 2011-04-24 | 2012-12-12 | 兰州大学 | 植物柳茶的一种用途 |
CN102641352B (zh) * | 2012-04-24 | 2014-01-08 | 杭州柳茶医药科技有限公司 | 一种柳茶有效部位提取物及其制备方法和用途 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001002579A (ja) | 1999-06-21 | 2001-01-09 | Iskra Ind Co Ltd | 柳茶(生薬)を有効成分として含有する脂質代謝調節剤 |
DE10160142A1 (de) * | 2001-12-07 | 2003-06-18 | Basf Ag | Verfahren zur Herstellung von Tetrahydrogeraniol |
JP2004283039A (ja) * | 2003-03-20 | 2004-10-14 | Riken Vitamin Co Ltd | 混合だしパック |
-
2005
- 2005-09-13 JP JP2005265430A patent/JP4328750B2/ja active Active
-
2006
- 2006-05-22 US US11/437,769 patent/US7538137B2/en not_active Expired - Fee Related
- 2006-05-26 CN CN2006100924043A patent/CN101077881B/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US7538137B2 (en) | 2009-05-26 |
JP2007077051A (ja) | 2007-03-29 |
CN101077881B (zh) | 2010-07-14 |
CN101077881A (zh) | 2007-11-28 |
US20070059339A1 (en) | 2007-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20100105766A1 (en) | Composition for inhibition or prevention of bone density reduction | |
KR101860165B1 (ko) | 식품, 약물, 화장품, 식이 보충제 및 생물제제의 성분으로서의 커피 추출물 | |
WO2011077800A1 (ja) | 高脂血症改善剤、並びに、貧血改善組成物、尿酸値低下組成物及び飲食品 | |
JP6294710B2 (ja) | 糖代謝改善剤 | |
JPH09176019A (ja) | 糖質分解消化酵素阻害剤並びにこれを配合した医薬品および飲食品 | |
KR102511361B1 (ko) | 해당화 추출물을 유효성분으로 포함하는 여성 폐경기 증후군 예방, 개선 또는 치료용 조성물 | |
JP2012051940A (ja) | ビワ葉抽出物を含有する飲食品及び医薬品 | |
JP4328750B2 (ja) | 新規な化合物、肥満改善剤、脂質代謝改善剤、血糖降下剤及び育毛改善剤 | |
EP1488797B1 (en) | Oral preprations having itching-relieving or antipruritic activity | |
JP2008222656A (ja) | 肥満改善および予防用組成物ならびに健康食品 | |
JP2013071909A (ja) | 脳内過酸化脂質蓄積抑制剤 | |
JP6977053B2 (ja) | ギ酸またはその薬学的に許容可能な塩を有効成分として含む肥満または肥満によって惹起された代謝症候群の予防または治療用組成物 | |
WO1999025197A1 (en) | Fenugreek compositions having reduced taste and odor and methods of use | |
KR101434129B1 (ko) | 항산화제 | |
JP3204348B2 (ja) | 動脈硬化抑制剤及びこれを含む食品又は医薬 | |
CN107019778A (zh) | 一种具有减肥和降血脂作用的组合物及其制备方法与用途 | |
CN1968694B (zh) | 具有镇痛作用的药物组合物 | |
CN111246849A (zh) | 学习记忆能力增强组合物 | |
JPWO2005082391A1 (ja) | ヒトβ3アドレナリン受容体アゴニスト剤 | |
KR20130093045A (ko) | 머루근 추출물을 포함하는 항비만용 조성물 | |
JP7557180B2 (ja) | PPARγ活性化用組成物及び糖取込み促進能向上用組成物 | |
JP6683897B1 (ja) | 深部体温低下剤 | |
KR101719015B1 (ko) | 프루네틴을 유효성분으로 함유하는 비만 또는 대사성 질환의 예방 또는 치료용 약학적 조성물 | |
WO2019159682A1 (ja) | ヒトのldlコレステロールを下げるゴーヤエキスの抽出方法 | |
JP4469406B1 (ja) | 血中コレステロール低下剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090602 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090615 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120619 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4328750 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150619 Year of fee payment: 6 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |